| Description |
Oxythiamine, an antimetabolite and a vitamin B1 antagonist, is a well-known thiamine antagonist and inhibitor of transketolase.
|
| Related Catalog |
|
| Target |
Vitamin B1, Thiamine, Transketolase[1].
|
| In Vitro |
Oxythiamine, an antimetabolite and a vitamin B1 antagonist, is a well-known thiamine antagonist and inhibitor of transketolase. Oxythiamine alters protein expression in a dose dependent manner. The level of alpha-enolase is increased by Oxythiamine treatment, while expression of 14-3-3 protein beta/alpha is suppressed by Oxythiamine at a stratified dose. Oxythiamine causes dynamic changes of total protein expression in time dependent fashion. Oxythiamine suppresses expression of cellular phosphor proteins significantly[2].
|
| Cell Assay |
Human pancreatic carcinoma cell line MIA PaCa-2 is used throughout the study. Experiments are set up in two groups: dose and time-dependent groups. For the dose-dependent group, the cells are stimulated with 5, 50 and 500 μM Oxythiamine (OT) for 48 hours, respectively. The unstimulated cells are considered as control. For the time-dependent group, the cells are stimulated with 50 μM Oxythiamine in MEM containing natural amino acids or 50% of 15 N algal amino acid mixture for 12 and 48 h. The unstimulated cells are considered as the zero time point. Each treatment is repeated four times with 10 mL/flask. The cell pellets are then collected for further analysis[2].
|
| References |
[1]. Moradi H, et al. Functional thiamine deficiency in end-stage renal disease: malnutrition despite ample nutrients. Kidney Int. 2016 Aug;90(2):252-254. [2]. Wang J, et al. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol. 2013 Jul 27;2:18.
|
